Advanced pneumatic compression device (APCD)Advanced pneumatic compression device (APCD) with revised compression programmingIndocyanine Green (IC-Green) →
Advanced pneumatic compression device (APCD): Single APCD treatment session at visit 1
Advanced pneumatic compression device (APCD) with revised compression programming: APCD with revised compression programming will be single treatment session at visit 2
Indocyanine Green (IC-Green): Indocyanine Green dye will be used to assess primary endpoint
Study summary
The goal of this pilot study is to learn if a revised method of compression improves lymphatic function compared to the current method of compression. The main questions:
• Does the revised method of compression improve lymph movement and lymphatic propulsion?
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. 18 years of age or older
2. A diagnosis of active lower extremity lymphedema, as assessed by medical history
3. Participant is a candidate for APCD treatment per the Flexitouch Plus indications for use
4. Must be able to provide informed consent prior to study participation
5. Willing and able to comply with the study protocol requirements and all study-related visit requirements
Exclusion Criteria:
1. Heart failure (acute pulmonary edema, decompensated acute heart failure)
2. Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
3. Severe peripheral artery disease (critical limb ischemia, including ischemic rest pain, arterial wounds or gangrene)
4. Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease) on the trunk or lower extremities
5. Active cancer or metastasis in the lower extremity lymphatic watersheds
6. Eczema, rash, scarring, or extensive tattoos at imaging sites
7. Participant is pregnant or trying to become pregnant
8. Participants with a history of allergy to iodides, who may be susceptible to iodine present in ICG formulation
9. Patients exhibiting Grade 3 or higher on the CTCAE v6.0 superficial soft tissue fibrosis scale
10. Body Mass Index (BMI) ≥40
11. Participants unable to recline on their backs for up to 60 consecutive minutes and walk in place or tolerate assisted lower extremity movement for 5 minutes
Primary outcome measure(s)
Lymphatic anatomy — Before and after 60-minute treatment in clinic with APCD • The distance (cm) that lymph travels from injection sites
Lymphatic propulsion — Before and after 60-minute treatment in clinic with APCD • Number of lymph propulsion events per minute
Trial sites (1)
Facility
City
Region
Status
UTHealth Houston (The University of Texas Health Science Center at Houston)
Houston
Texas
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.